Clinical Trial Update: Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk. [Phase 3]

View source ↗

Summary

Phase 3 trial assessing 4F-PCC (Octaplex) versus Beriplex/Kcentra for reversal of vitamin K antagonist anticoagulation in patients needing urgent surgery with s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anticoagulation Reversal
• Urgent Surgery-related Bleeding Risk

Drugs mentioned

• Beriplex P/N (prothrombin complex concentrate)
• OCTAPLEX

Snippet

Sponsor: Octapharma | Conditions: Significant Bleeding Risk | Phase 3 | Status: COMPLETED | Results posted: 2023-03-08